| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 44,870 | 62,242 | ||
| Accounts receivable | 4 | 0 | ||
| Marketable securities | 0 | 0 | ||
| Prepaid expenses | 5,857 | 7,450 | ||
| Assets held for sale | 126 | 140 | ||
| Contract asset | 0 | 0 | ||
| Other current assets | 848 | 427 | ||
| Total current assets | 51,705 | 70,259 | ||
| Restricted cash | 26,342 | 22,564 | ||
| Property, equipment, and softwarenet | 2,026 | 2,356 | ||
| Intangible assetsnet | 985 | 605 | ||
| Right-of-use assetsnet | 6,138 | 6,462 | ||
| Investment in equity securities | 744 | 744 | ||
| Note receivablenet | 5,370 | 5,730 | ||
| Other assets | 200 | 208 | ||
| Total assets | 93,510 | 108,928 | ||
| Accounts payable | 1,340 | 1,121 | ||
| Accrued compensation | 3,157 | 2,450 | ||
| Accrued research and development expenses | 1,297 | 991 | ||
| Deferred revenue | 6,248 | 5,989 | ||
| Lease liabilities | 1,458 | 1,411 | ||
| Other current liabilities | 611 | 721 | ||
| Current liabilities of discontinued operations | 885 | 885 | ||
| Total current liabilities | 14,996 | 13,568 | ||
| Loan payable | 22,374 | 22,354 | ||
| Deferred revenue | 19,957 | 20,225 | ||
| Lease liabilities | 5,296 | 5,680 | ||
| Warrant liability | 4,026 | 2,847 | ||
| Contract liabilities | 10,000 | 10,000 | ||
| Other noncurrent liabilities | 227 | 200 | ||
| Total liabilities | 76,876 | 74,874 | ||
| Common stock 0.000005 par value 200,000,000 shares authorized as of june 30, 2025 and december 31, 2024 11,663,996 shares issued and 11,636,981 shares outstanding as of june 30, 2025 8,229,730 shares issued and 8,202,715 shares outstanding as of december 31, 2024 | 1 | 1 | ||
| Additional paid-in capital | 565,906 | 561,554 | ||
| Accumulated deficit | -548,321 | -526,549 | ||
| Treasury stock | 952 | 952 | ||
| Total stockholders equity | 16,634 | 34,054 | ||
| Total liabilities and stockholders equity | 93,510 | 108,928 | ||
PRECISION BIOSCIENCES INC (DTIL)
PRECISION BIOSCIENCES INC (DTIL)